Last reviewed: June 17, 2026
Last updated: June 17, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
There is no specific weight requirement to start semaglutide therapy—eligibility centers on your body mass index (BMI), medical history, and overall health profile. The FDA-approved injectable versions target individuals with a BMI of 30 or higher, or a BMI of 27 or higher with weight-related health conditions. PlexusDx compounded semaglutide injections begin at $149 per month and serve patients nationwide without requiring insurance.
BMI Thresholds for Semaglutide Eligibility
Body mass index (BMI) is the primary clinical measure used to determine semaglutide candidacy. A BMI of 30 or above qualifies patients for weight loss therapy, as this threshold is associated with obesity-related health risks including type 2 diabetes, hypertension, and cardiovascular disease. If your BMI falls between 27 and 29.9, you may still qualify if you have at least one weight-related condition such as sleep apnea, joint problems, or elevated blood pressure.
PlexusDx evaluates each patient's complete health picture rather than relying on weight alone. Your consultation with a PlexusDx clinician will assess your BMI, current medications, metabolic history, and personal weight loss goals to determine if semaglutide is appropriate for your situation. This individualized approach helps identify who will benefit most from treatment.
Medical Conditions That Lower Weight Thresholds
Having obesity-related comorbidities can make you eligible for semaglutide even if your BMI is below 30. Common qualifying conditions include type 2 diabetes, prediabetes, hypertension, dyslipidemia, obstructive sleep apnea, and a history of cardiovascular events. These conditions are markers that excess weight is already affecting your health, making weight loss therapy medically necessary.
Patients with a BMI between 27 and 29.9 combined with one or more weight-related health problems have documented benefits from semaglutide in clinical trials. Studies show that semaglutide reduces cardiovascular risk, improves blood sugar control, and decreases blood pressure independently of weight loss magnitude. PlexusDx clinicians review your medical records to identify these health factors during your initial assessment.
How Genetics Influence Your Semaglutide Response
Your individual genetic makeup affects how effectively semaglutide works for weight loss, independent of your starting weight. The PlexusDx Precision Peptide Genetic Test analyzes 14 metabolic pathways and 49 peptides, including variants in the GLP-1 receptor gene (rs6923761) and the GIPR gene (rs1800437) that directly influence how your body responds to GLP-1 agonists. Carriers of certain genetic variants may experience more robust weight loss and better appetite suppression on semaglutide.
Genetic testing also identifies your predisposition for hunger hormone signaling, insulin sensitivity, and fat metabolism pathways. Understanding these insights helps PlexusDx clinicians personalize your starting dose and trajectory, optimizing your outcomes whether you begin treatment at a BMI of 30 or higher. The Precision Peptide Genetic Test is available as a $99 add-on after your first month of treatment.
Access to Compounded Semaglutide Without Weight-Based Barriers
PlexusDx removes administrative barriers to semaglutide access by serving all 50 states without requiring insurance approval or pre-authorization delays. Compounded semaglutide from licensed 503A pharmacies is significantly more affordable than brand-name formulations, with pricing starting at $149 per month flat—your dose may need to go up, but your price won't. This pricing model ensures that patients can affordably access treatment regardless of their starting weight or expected dose progression.
Unlike traditional healthcare settings, PlexusDx does not implement weight-based gatekeeping or require a minimum weight to begin therapy. A PlexusDx clinician will complete a telehealth assessment, review your medical history and BMI, and determine your individual suitability for treatment. HSA and FSA accounts are accepted, further reducing out-of-pocket costs for eligible patients.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
What is the exact weight I need to reach to qualify for semaglutide?
There is no single weight requirement—eligibility is based on BMI (typically 30 or higher, or 27+ with weight-related health conditions) and overall health profile. PlexusDx clinicians assess each patient individually during consultation rather than applying a fixed weight threshold.
Can I get semaglutide if my BMI is below 30?
Yes, if you have a BMI between 27 and 29.9 and at least one weight-related condition such as type 2 diabetes, sleep apnea, or hypertension, you qualify for semaglutide therapy. Clinical evidence demonstrates weight loss benefits and cardiovascular risk reduction in this population.
How much does PlexusDx compounded semaglutide cost per month?
PlexusDx compounded semaglutide injections start at $149 per month regardless of your dose level—your dose may need to go up, but your price won't. No insurance is required, and HSA/FSA accounts are accepted for all patients.
Does compounded semaglutide work as well as brand-name Ozempic?
PlexusDx compounded semaglutide is manufactured by licensed 503A pharmacies following FDA guidelines for strength, purity, and safety. Clinical evidence for semaglutide's mechanism and efficacy applies to all pharmaceutical-grade formulations, though individual response varies based on genetics and health factors.
How does the Precision Peptide Genetic Test help predict my weight loss success?
The PlexusDx Precision Peptide Genetic Test analyzes variants in GLP-1 receptor, GIPR, FTO, and MC4R genes that directly influence appetite regulation and weight loss response to semaglutide. Understanding your genetic predispositions helps your clinician optimize your starting dose and treatment plan for maximum results.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Do You Lose Weight on Wegovy Without Dieting? Exploring the Science and Realities
Is Zepbound Better than Wegovy for Weight Loss?